Mono Pharmacare Ltd vs Syncom Formulations India Ltd Stock Comparison
Mono Pharmacare Ltd vs Syncom Formulations India Ltd Stock Comparison
Last Updated on: May 06, 2026
Key Highlights
The Latest Trading Price of Mono Pharmacare Ltd is ₹ 13.1 as of 06 May 14:57
. The P/E Ratio of Mono Pharmacare Ltd changed from 32 on March 2024 to 13.2 on March 2025 . This represents a CAGR of -35.77% over 2 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Mono Pharmacare Ltd changed from ₹ 77.92 crore on March 2024 to ₹ 40.81 crore on March 2025 . This represents a CAGR of -27.63% over 2 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Mono Pharmacare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Mono Pharmacare Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Mono Pharmacare Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97%
The Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .
About Mono Pharmacare Ltd
Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products.
The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing.
Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.
About Syncom Formulations (India) Ltd
Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh.
Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.
The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.
FAQs for the comparison of Mono Pharmacare Ltd and Syncom Formulations (India) Ltd
Which company has a larger market capitalization, Mono Pharmacare Ltd or Syncom Formulations (India) Ltd?
Market cap of Mono Pharmacare Ltd is 22 Cr while Market cap of Syncom Formulations (India) Ltd is 1,321 Cr
What are the key factors driving the stock performance of Mono Pharmacare Ltd and Syncom Formulations (India) Ltd?
The stock performance of Mono Pharmacare Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Mono Pharmacare Ltd and Syncom Formulations (India) Ltd?
As of May 6, 2026, the Mono Pharmacare Ltd stock price is INR ₹12.5. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.06.
How do dividend payouts of Mono Pharmacare Ltd and Syncom Formulations (India) Ltd compare?
To compare the dividend payouts of Mono Pharmacare Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.